Developer docs
API playgroundTry for free, no card

Search company profiles

IntelliGenome

Full company profile

uuid00hfycc

Namestring
IntelliGenome
Legal namestring
IntelliGenome, Inc.
Company typeenum
Private
Founded yearint
2022
Descriptiontext

IntelliGenome, Inc. is a Houston-based molecular diagnostics company founded in July 2022 that develops CRISPR-based blood tests for infectious disease detection and treatment monitoring, with tuberculosis (TB) as its lead indication. The company's core technology combines high-efficiency DNA polymerase amplification with a thermostable protein-enhanced CRISPR-Cas fluorescence detection system to identify pathogen-specific DNA sequences at single-nucleotide resolution. Its product portfolio includes the CRISPR-TB Benchtop Assay for high-throughput use in CLIA-certified laboratories, the CRISPR-TB Point of Care Blood Assay built on its proprietary "Lab in Tube" (LIT) portable platform with a reusable fluorescent reader and disposable test kits, and the flagship CRISPR-TB Blood Test designed to detect Mycobacterium tuberculosis cell-free DNA in human serum and EDTA plasma. Research-stage extensions target nontuberculous mycobacteria (NTM) cfDNA detection in blood and oncology cfDNA biomarker assays.

The company's commercial model operates through three primary channels: laboratory services performed by Ruthenium Diagnostics, LLC (a CLIA-certified high-complexity laboratory in Houston under CLIA #45D2310559, billing under CPT/PLA Code PLA 102138), exclusive international distribution partnerships (CTR Scientific in Mexico and Velez Lab S.A.S. in Colombia), and a wholly owned APAC subsidiary (Hangzhou Intelligenome Biotechnology Co., Ltd., established May 2025). Revenue also derives from NIH-funded R&D subaward agreements, including a March 2026 subaward through Cornell University to develop a portable lab-in-tube TB diagnostic. The company has secured FDA Breakthrough Device Designation (January 2025), CE-IVDD certification, and INVIMA sanitary registration in Colombia (June 2026), with multicenter clinical studies planned across the US, Mexico, and Germany.

IntelliGenome serves healthcare laboratories, point-of-care clinics, and resource-limited healthcare settings, with particular focus on patient populations underserved by sputum-based TB diagnostics including pediatric (12% of TB cases), HIV-co-infected (8.2% of cases), and extra-pulmonary TB patients. The platform's primary value proposition is rapid (hours versus weeks for culture), non-sputum-based TB detection from blood, addressing an estimated 3.1 million missed active TB cases annually and a US TB testing market exceeding $2 billion per year. Leadership includes CEO Wilson Zhang, M.D. (20 years in diagnostics corporate development and M&A), CTO Bo Ning, Ph.D. (lead designer of the CRISPR detection chemistry), and CSO/Founder Tony Hu, Ph.D. (AIMBE Fellow, formerly Tulane University, now Tsinghua University).

Short descriptiontext

IntelliGenome is a Houston-based molecular diagnostics company founded in 2022 that develops CRISPR-based blood tests for infectious disease detection, with tuberculosis as its lead indication. It serves healthcare laboratories, point-of-care clinics, and resource-limited settings through CLIA lab services, exclusive international distribution partners, and a wholly owned APAC subsidiary.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, CRISPR diagnostic testing, tuberculosis detection, infectious disease testing, point-of-care diagnostics
Industry4 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CRISPR-TB Blood Test
TypeOne Time License
Description

The company generates revenue through sale of its CRISPR-TB Blood Test kits. The test is performed by Ruthenium Diagnostics, LLC (CLIA #45D2310559) in collaboration with Intelligenome. Test is categorized as Proprietary Laboratory Analysis (PLA) with CPT/PLA Code: PLA 102138. Revenue is derived from laboratory service fees for molecular diagnostic testing performed on patient samples.

intelligenome-us.com
2Point-of-Care Testing Solutions
TypeHardware Sales
Description

Revenue from portable Lab in Tube (LIT) diagnostic devices and disposable test kits. The system includes portable fluorescent readers sold separately and single-use disposable test kit components for on-site TB testing.

intelligenome-us.com
3NIH-Funded R&D Collaboration
TypeLicensing Royalties
Description

IntelliGenome receives funding through R&D subaward agreements with Cornell University as part of NIH-funded programs for developing rapid, low-cost portable TB diagnostics.

intelligenome-us.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others
Pricing details1 tier
1CRISPR-TB Blood Test - Laboratory-based testing service
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Test developed and performed by Ruthenium Diagnostics, LLC (CLIA #45D2310559). CPT/PLA Code: PLA 102138. Pricing not publicly disclosed; quote-based arrangement through laboratory services.

intelligenome-us.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Lab in Tube (LIT)
Description

Advanced point-of-care molecular diagnostic platform designed for portability, ease of use, and accessibility, integrating all necessary reagents to isolate and detect Mtb cfDNA in a single compact device.

intelligenome-us.com
+1 more record
Core offering1 text field

IntelliGenome develops and commercializes CRISPR-based molecular diagnostic tests that detect pathogen cell-free DNA in blood samples, with the lead application being tuberculosis detection. The company offers a high-throughput CRISPR-TB Benchtop Assay for clinical laboratories and a portable CRISPR-TB Point of Care Blood Assay built on its proprietary Lab in Tube (LIT) platform. Research-stage offerings extend the platform to nontuberculous mycobacteria (NTM) detection and oncology cfDNA biomarker detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First qualitative real-time PCR assay combining CRISPR technology to detect Mtb cell-free DNA in human serum and EDTA plasma
+2 more records
Product overview1 text field

IntelliGenome offers a CRISPR-based molecular diagnostic platform with two main product lines: (1) CRISPR-TB Benchtop Assay for high-throughput laboratory testing in CLIA-certified facilities, and (2) CRISPR-TB Point of Care Blood Assay featuring the Lab in Tube (LIT) portable system for decentralized testing. The platform leverages CRISPR-Cas technology combined with PCR amplification and fluorescent detection to identify pathogen-specific DNA sequences with high sensitivity. The first commercial product is the CRISPR-TB Blood Test for tuberculosis detection from blood samples, addressing pulmonary and extra-pulmonary TB across all patient populations. Research-stage offerings include NTM cfDNA Detection and Oncology cfDNA Detection assays.

Product and service5 records
1CRISPR-TB Benchtop Assay
CategoryLaboratory Diagnostic Test
Description

High-throughput tuberculosis diagnostic assay designed for CLIA-certified laboratories. Detects Mycobacterium tuberculosis cell-free DNA in plasma or serum using CRISPR-based detection combined with real-time PCR amplification, delivering results in hours for pediatric, geriatric, and critically ill populations.

2CRISPR-TB Point of Care Blood Assay
CategoryPoint-of-Care Diagnostic Platform
Description

Self-contained point-of-care molecular diagnostic solution for ultra-sensitive tuberculosis detection from blood samples. Built on the proprietary Lab in Tube (LIT) platform integrating DNA amplification, CRISPR detection, and TB identification modules in a portable device readable with a portable fluorescent reader.

3CRISPR-TB Blood Test
CategoryLaboratory Diagnostic Test
Description

Qualitative in vitro diagnostic test for detection of Mycobacterium tuberculosis complex cell-free DNA in blood samples using CRISPR technology with quantitative PCR. Developed and performed by Ruthenium Diagnostics, LLC (CLIA #45D2310559) in collaboration with IntelliGenome, billed under CPT/PLA Code PLA 102138.

4NTM cfDNA Detection Assay
CategoryResearch Diagnostic Assay
Description

Research-use assay using an isolation-free multiplex RPA-CRISPR detection method to detect nontuberculous mycobacteria cell-free DNA in blood samples. Targets patients with underlying lung conditions such as bronchiectasis or COPD who are at risk for NTM infections.

5Oncology cfDNA Detection
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-29
Description

Velez Lab S.A.S. appointed as exclusive distribution partner for Colombia under a long-term commercial agreement. The partnership focuses on expanding access to innovative tuberculosis diagnostic solutions throughout Colombia. Plans include collaboration with leading healthcare institutions, researchers, and public health stakeholders to advance evidence generation in pediatric TB, EPTB, and other high-priority populations.

2CTR Scientific (Control Técnico y Representaciones S.A. de C.V.)
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-15
Description

CTR Scientific serves as IntelliGenome's exclusive distribution partner in Mexico. The partnership supports evaluation, commercialization, and future adoption of the CRISPR-TB Blood Test. CTR Scientific leverages its extensive network and expertise to accelerate market development and evaluation throughout Mexico, particularly for pediatric, extrapulmonary, and vulnerable populations.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable TB diagnostic solution as part of an NIH-funded program. IntelliGenome contributes its CRISPR-based point-of-care testing platform to create a portable lab-in-tube assay for TB detection from respiratory and blood samples, expanding diagnostic access in settings with limited laboratory infrastructure.

4Ruthenium Diagnostics, LLC
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Ruthenium Diagnostics, LLC (CLIA #45D2310559) develops and performs the CRISPR-TB Blood Test in collaboration with IntelliGenome. Located at 9440 Bellaire Blvd. Suite 110B, Houston, TX 77036. The laboratory performs testing under CLIA regulations for high-complexity testing, providing the primary commercial channel for IntelliGenome's test.

intelligenome-us.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Tony Hu's research group at Tulane University developed the foundational CRISPR detection technology over more than a decade. IntelliGenome licensed and commercialized this technology. Tony Hu serves as AIMBE Fellow, Founder, and Chief Science Advisor to IntelliGenome. The technology represents the culmination of research published in Lancet Microbe and other leading journals.

6Hangzhou Intelligenome Biotechnology Co., Ltd.
Strategic tierCoreTypeOthers
Description

Wholly owned company established May 20 as part of APAC expansion. Represents IntelliGenome's continued commitment to strengthening local support, advancing research collaboration, and expanding access to innovative molecular diagnostic solutions across the Asia-Pacific region.

intelligenome-us.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sherlock Biosciences is a CRISPR-based molecular diagnostics company with SHERLOCK and INSPECTR platforms. It is a direct CRISPR-diagnostics peer, pursuing CRISPR-Cas detection across infectious disease and oncology indications overlapping with IntelliGenome's roadmap.

2Abbott
TypeBroad incumbent
Description

Abbott's m2000 RealTime MTB and Alinity m systems are widely deployed molecular TB assays in reference labs and hospitals. Abbott is a broad incumbent that competes with IntelliGenome on TB benchtop testing throughput and global lab market share.

TypeDirect peer
Description

Cepheid's GeneXpert MTB/RIF is the dominant molecular TB diagnostic on the market. It is the most direct competitor to IntelliGenome's CRISPR-TB platform, addressing the same TB testing market from hospital and reference-lab settings, albeit with a sputum/cartridge-based workflow rather than blood-based CRISPR detection.

TypeEmerging player
Description

Bioneer offers the AccuPower TB real-time PCR kit for molecular TB detection, with a focus on emerging markets. It is comparable to IntelliGenome as a regional/emerging molecular TB diagnostics player targeting cost-sensitive and decentralized settings.

TypeBroad incumbent
Description

QIAGEN offers QuantiFERON-TB Gold Plus and the QIAreach QuantiFERON-TB latent TB assay, plus sample-prep and PCR workflows used in TB labs. It is a broad incumbent in TB and molecular diagnostics that IntelliGenome's leadership has deep prior ties to and competes with across workflow stages.

TypeDirect peer
Description

Molbio's Truenat MTB is a chip-based real-time PCR molecular TB test designed for decentralized and POC use. It is directly comparable to IntelliGenome's Lab-in-Tube point-of-care platform in targeting rapid, decentralized TB detection in resource-limited settings.

TypeBroad incumbent
Description

Roche's cobas MTB and cobas 6800/8800 systems are established high-throughput molecular TB diagnostics in central laboratories. Roche is a broad incumbent competing with IntelliGenome's CRISPR-TB Benchtop Assay for the same high-volume reference-lab TB testing market.

TypeDirect peer
Description

Hain Lifescience (now part of Bruker) provides the FluoroType MTB and related molecular TB/mycobacteria assays. It directly competes with IntelliGenome's CRISPR-TB Benchtop Assay in CLIA-certified and clinical mycobacteriology laboratory workflows.

TypeDirect peer
Description

Mammoth Biosciences is a CRISPR diagnostics company commercializing a Cas12-based DETECTR platform. It is a direct CRISPR-diagnostics peer developing molecular infectious-disease and oncology assays using the same underlying CRISPR-Cas detection chemistry that IntelliGenome applies to TB.

TypeEmerging player
Description

QuantuMDx is developing the Q-POC rapid molecular diagnostic platform for infectious diseases including TB at the point of care. It is an emerging POC molecular diagnostics peer with overlapping TB and decentralized-testing positioning to IntelliGenome's Lab-in-Tube.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IntelliGenome

Molecular Diagnosticsintelligenome-us.com

IntelliGenome is a Houston-based molecular diagnostics company founded in 2022 that develops CRISPR-based blood tests for infectious disease detection, with tuberculosis as its lead indication. It serves healthcare laboratories, point-of-care clinics, and resource-limited settings through CLIA lab services, exclusive international distribution partners, and a wholly owned APAC subsidiary.

What IntelliGenome does

IntelliGenome, Inc. is a Houston-based molecular diagnostics company founded in July 2022 that develops CRISPR-based blood tests for infectious disease detection and treatment monitoring, with tuberculosis (TB) as its lead indication. The company's core technology combines high-efficiency DNA polymerase amplification with a thermostable protein-enhanced CRISPR-Cas fluorescence detection system to identify pathogen-specific DNA sequences at single-nucleotide resolution. Its product portfolio includes the CRISPR-TB Benchtop Assay for high-throughput use in CLIA-certified laboratories, the CRISPR-TB Point of Care Blood Assay built on its proprietary "Lab in Tube" (LIT) portable platform with a reusable fluorescent reader and disposable test kits, and the flagship CRISPR-TB Blood Test designed to detect Mycobacterium tuberculosis cell-free DNA in human serum and EDTA plasma. Research-stage extensions target nontuberculous mycobacteria (NTM) cfDNA detection in blood and oncology cfDNA biomarker assays.

The company's commercial model operates through three primary channels: laboratory services performed by Ruthenium Diagnostics, LLC (a CLIA-certified high-complexity laboratory in Houston under CLIA #45D2310559, billing under CPT/PLA Code PLA 102138), exclusive international distribution partnerships (CTR Scientific in Mexico and Velez Lab S.A.S. in Colombia), and a wholly owned APAC subsidiary (Hangzhou Intelligenome Biotechnology Co., Ltd., established May 2025). Revenue also derives from NIH-funded R&D subaward agreements, including a March 2026 subaward through Cornell University to develop a portable lab-in-tube TB diagnostic. The company has secured FDA Breakthrough Device Designation (January 2025), CE-IVDD certification, and INVIMA sanitary registration in Colombia (June 2026), with multicenter clinical studies planned across the US, Mexico, and Germany.

IntelliGenome serves healthcare laboratories, point-of-care clinics, and resource-limited healthcare settings, with particular focus on patient populations underserved by sputum-based TB diagnostics including pediatric (12% of TB cases), HIV-co-infected (8.2% of cases), and extra-pulmonary TB patients. The platform's primary value proposition is rapid (hours versus weeks for culture), non-sputum-based TB detection from blood, addressing an estimated 3.1 million missed active TB cases annually and a US TB testing market exceeding $2 billion per year. Leadership includes CEO Wilson Zhang, M.D. (20 years in diagnostics corporate development and M&A), CTO Bo Ning, Ph.D. (lead designer of the CRISPR detection chemistry), and CSO/Founder Tony Hu, Ph.D. (AIMBE Fellow, formerly Tulane University, now Tsinghua University).

IntelliGenome firmographics

Firmographics
Name
IntelliGenome
Legal name
IntelliGenome, Inc.
Website
https://intelligenome-us.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
IntelliGenome is a Houston-based molecular diagnostics company founded in 2022 that develops CRISPR-based blood tests for infectious disease detection, with tuberculosis as its lead indication. It serves healthcare laboratories, point-of-care clinics, and resource-limited settings through CLIA lab services, exclusive international distribution partners, and a wholly owned APAC subsidiary.
Ownership category
akta.pro rank

IntelliGenome industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics
  • CRISPR diagnostic testing
  • Tuberculosis detection
  • Infectious disease testing
  • Point-of-care diagnostics

Where IntelliGenome is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

IntelliGenome business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

  1. CRISPR-TB Blood Test: The company generates revenue through sale of its CRISPR-TB Blood Test kits. The test is performed by Ruthenium Diagnostics, LLC (CLIA #45D2310559) in collaboration with Intelligenome. Test is categorized as Proprietary Laboratory Analysis (PLA) with CPT/PLA Code: PLA 102138. Revenue is derived from laboratory service fees for molecular diagnostic testing performed on patient samples.
  2. Point-of-Care Testing Solutions: Revenue from portable Lab in Tube (LIT) diagnostic devices and disposable test kits. The system includes portable fluorescent readers sold separately and single-use disposable test kit components for on-site TB testing.
  3. NIH-Funded R&D Collaboration: IntelliGenome receives funding through R&D subaward agreements with Cornell University as part of NIH-funded programs for developing rapid, low-cost portable TB diagnostics.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goCRISPR-TB Blood Test - Laboratory-based testing service

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

IntelliGenome product offering

Product offering

Core offering

IntelliGenome develops and commercializes CRISPR-based molecular diagnostic tests that detect pathogen cell-free DNA in blood samples, with the lead application being tuberculosis detection. The company offers a high-throughput CRISPR-TB Benchtop Assay for clinical laboratories and a portable CRISPR-TB Point of Care Blood Assay built on its proprietary Lab in Tube (LIT) platform. Research-stage offerings extend the platform to nontuberculous mycobacteria (NTM) detection and oncology cfDNA biomarker detection.

Product overview

IntelliGenome offers a CRISPR-based molecular diagnostic platform with two main product lines: (1) CRISPR-TB Benchtop Assay for high-throughput laboratory testing in CLIA-certified facilities, and (2) CRISPR-TB Point of Care Blood Assay featuring the Lab in Tube (LIT) portable system for decentralized testing. The platform leverages CRISPR-Cas technology combined with PCR amplification and fluorescent detection to identify pathogen-specific DNA sequences with high sensitivity. The first commercial product is the CRISPR-TB Blood Test for tuberculosis detection from blood samples, addressing pulmonary and extra-pulmonary TB across all patient populations. Research-stage offerings include NTM cfDNA Detection and Oncology cfDNA Detection assays.

Differentiator

Problem solved

Functional benefit

Brands

  • Lab in Tube (LIT): Advanced point-of-care molecular diagnostic platform designed for portability, ease of use, and accessibility, integrating all necessary reagents to isolate and detect Mtb cfDNA in a single compact device.
  • CRISPR-TB Blood Test

Products and services

  • CRISPR-TB Benchtop Assay High-throughput tuberculosis diagnostic assay designed for CLIA-certified laboratories. Detects Mycobacterium tuberculosis cell-free DNA in plasma or serum using CRISPR-based detection combined with real-time PCR amplification, delivering results in hours for pediatric, geriatric, and critically ill populations.
  • CRISPR-TB Point of Care Blood Assay Self-contained point-of-care molecular diagnostic solution for ultra-sensitive tuberculosis detection from blood samples. Built on the proprietary Lab in Tube (LIT) platform integrating DNA amplification, CRISPR detection, and TB identification modules in a portable device readable with a portable fluorescent reader.
  • CRISPR-TB Blood Test Qualitative in vitro diagnostic test for detection of Mycobacterium tuberculosis complex cell-free DNA in blood samples using CRISPR technology with quantitative PCR. Developed and performed by Ruthenium Diagnostics, LLC (CLIA #45D2310559) in collaboration with IntelliGenome, billed under CPT/PLA Code PLA 102138.
  • NTM cfDNA Detection Assay Research-use assay using an isolation-free multiplex RPA-CRISPR detection method to detect nontuberculous mycobacteria cell-free DNA in blood samples. Targets patients with underlying lung conditions such as bronchiectasis or COPD who are at risk for NTM infections.
  • Oncology cfDNA Detection

Quantifiable outcome

  • First qualitative real-time PCR assay combining CRISPR technology to detect Mtb cell-free DNA in human serum and EDTA plasma
  • +2 more outcomes

Companies that use IntelliGenome

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles2 records

IntelliGenome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

IntelliGenome partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Velez Lab S.A.S.coreChannel Partner/ Reseller/ Distributor · 29 June 2026Velez Lab S.A.S. appointed as exclusive distribution partner for Colombia under a long-term commercial agreement. The partnership focuses on expanding access to innovative tuberculosis diagnostic solutions throughout Colombia. Plans include collaboration with leading healthcare institutions, researchers, and public health stakeholders to advance evidence generation in pediatric TB, EPTB, and other high-priority populations.
  • CTR Scientific (Control Técnico y Representaciones S.A. de C.V.)coreChannel Partner/ Reseller/ Distributor · 15 June 2026CTR Scientific serves as IntelliGenome's exclusive distribution partner in Mexico. The partnership supports evaluation, commercialization, and future adoption of the CRISPR-TB Blood Test. CTR Scientific leverages its extensive network and expertise to accelerate market development and evaluation throughout Mexico, particularly for pediatric, extrapulmonary, and vulnerable populations.
  • Cornell UniversitycoreStrategic or Co-development Partner · 23 March 2026R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable TB diagnostic solution as part of an NIH-funded program. IntelliGenome contributes its CRISPR-based point-of-care testing platform to create a portable lab-in-tube assay for TB detection from respiratory and blood samples, expanding diagnostic access in settings with limited laboratory infrastructure.
  • Ruthenium Diagnostics, LLCcoreImplementation/ SI/ Consulting PartnerRuthenium Diagnostics, LLC (CLIA #45D2310559) develops and performs the CRISPR-TB Blood Test in collaboration with IntelliGenome. Located at 9440 Bellaire Blvd. Suite 110B, Houston, TX 77036. The laboratory performs testing under CLIA regulations for high-complexity testing, providing the primary commercial channel for IntelliGenome's test.
  • Tulane University (Tony Hu Research Group)coreStrategic or Co-development PartnerProfessor Tony Hu's research group at Tulane University developed the foundational CRISPR detection technology over more than a decade. IntelliGenome licensed and commercialized this technology. Tony Hu serves as AIMBE Fellow, Founder, and Chief Science Advisor to IntelliGenome. The technology represents the culmination of research published in Lancet Microbe and other leading journals.
  • Hangzhou Intelligenome Biotechnology Co., Ltd.coreOthersWholly owned company established May 20 as part of APAC expansion. Represents IntelliGenome's continued commitment to strengthening local support, advancing research collaboration, and expanding access to innovative molecular diagnostic solutions across the Asia-Pacific region.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

IntelliGenome competitors and assessment

Company assessment

Direct peers

  • Sherlock Biosciences: Sherlock Biosciences is a CRISPR-based molecular diagnostics company with SHERLOCK and INSPECTR platforms. It is a direct CRISPR-diagnostics peer, pursuing CRISPR-Cas detection across infectious disease and oncology indications overlapping with IntelliGenome's roadmap.
  • Cepheid (Danaher): Cepheid's GeneXpert MTB/RIF is the dominant molecular TB diagnostic on the market. It is the most direct competitor to IntelliGenome's CRISPR-TB platform, addressing the same TB testing market from hospital and reference-lab settings, albeit with a sputum/cartridge-based workflow rather than blood-based CRISPR detection.
  • Molbio Diagnostics: Molbio's Truenat MTB is a chip-based real-time PCR molecular TB test designed for decentralized and POC use. It is directly comparable to IntelliGenome's Lab-in-Tube point-of-care platform in targeting rapid, decentralized TB detection in resource-limited settings.
  • Hain Lifescience (Bruker): Hain Lifescience (now part of Bruker) provides the FluoroType MTB and related molecular TB/mycobacteria assays. It directly competes with IntelliGenome's CRISPR-TB Benchtop Assay in CLIA-certified and clinical mycobacteriology laboratory workflows.
  • Mammoth Biosciences: Mammoth Biosciences is a CRISPR diagnostics company commercializing a Cas12-based DETECTR platform. It is a direct CRISPR-diagnostics peer developing molecular infectious-disease and oncology assays using the same underlying CRISPR-Cas detection chemistry that IntelliGenome applies to TB.

Broad incumbents

  • Abbott: Abbott's m2000 RealTime MTB and Alinity m systems are widely deployed molecular TB assays in reference labs and hospitals. Abbott is a broad incumbent that competes with IntelliGenome on TB benchtop testing throughput and global lab market share.
  • QIAGEN: QIAGEN offers QuantiFERON-TB Gold Plus and the QIAreach QuantiFERON-TB latent TB assay, plus sample-prep and PCR workflows used in TB labs. It is a broad incumbent in TB and molecular diagnostics that IntelliGenome's leadership has deep prior ties to and competes with across workflow stages.
  • Roche Diagnostics: Roche's cobas MTB and cobas 6800/8800 systems are established high-throughput molecular TB diagnostics in central laboratories. Roche is a broad incumbent competing with IntelliGenome's CRISPR-TB Benchtop Assay for the same high-volume reference-lab TB testing market.

Emerging players

  • Bioneer: Bioneer offers the AccuPower TB real-time PCR kit for molecular TB detection, with a focus on emerging markets. It is comparable to IntelliGenome as a regional/emerging molecular TB diagnostics player targeting cost-sensitive and decentralized settings.
  • QuantuMDx: QuantuMDx is developing the Q-POC rapid molecular diagnostic platform for infectious diseases including TB at the point of care. It is an emerging POC molecular diagnostics peer with overlapping TB and decentralized-testing positioning to IntelliGenome's Lab-in-Tube.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IntelliGenome social profiles

Digital presence

IntelliGenome compliance and trust

Trust signal

Compliance4 records

IntelliGenome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IntelliGenome leadership team

Management profile

Number of profiles

Profiles7 records

IntelliGenome subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IntelliGenome funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IntelliGenome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IntelliGenome

What does IntelliGenome do?

IntelliGenome develops and commercializes CRISPR-based molecular diagnostic tests that detect pathogen cell-free DNA in blood samples, with the lead application being tuberculosis detection. The company offers a high-throughput CRISPR-TB Benchtop Assay for clinical laboratories and a portable CRISPR-TB Point of Care Blood Assay built on its proprietary Lab in Tube (LIT) platform. Research-stage offerings extend the platform to nontuberculous mycobacteria (NTM) detection and oncology cfDNA biomarker detection.

Is IntelliGenome a public or private company?

IntelliGenome is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IntelliGenome founded?

IntelliGenome was founded in 2022. It employs 11 to 50 people.

Where is IntelliGenome based?

IntelliGenome is headquartered in Houston, United States, in the North America region.

How does IntelliGenome make money?

Three revenue lines are on record. CRISPR-TB Blood Test is the primary driver. The others are point-of-Care Testing Solutions and NIH-Funded R&D Collaboration.

Who are IntelliGenome's main competitors?

Direct peers on record are Sherlock Biosciences, Cepheid (Danaher), Molbio Diagnostics, Hain Lifescience (Bruker) and Mammoth Biosciences. Broad incumbents are Abbott, QIAGEN and Roche Diagnostics. Emerging players are Bioneer and QuantuMDx.

Does IntelliGenome have an API?

No public API is recorded for IntelliGenome.

What industry is IntelliGenome in?

IntelliGenome's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarIntelliGenome Appoints SIMED as Exclusive Distributor for CRISPR-TB™ in Peru and EcuadorIntelliGenome appointed SIMED as exclusive distributor for its CRISPR-TB blood test in Peru and Ecuador. The company received DIGEMID registration approval in Peru, enabling commercial distribution, while SIMED will initiate registration in Ecuador. The partnership expands IntelliGenome's Latin American presence.Respiratory TherapyIntelligenome, Cornell Partner on Portable TB DiagnosticIntelligenome and Cornell University have entered into a research agreement to develop a portable, low-cost diagnostic tool for tuberculosis (TB) as part of a NIH-funded program. The project aims to create a rapid, non-sputum based test that uses CRISPR technology to detect cell-free DNA from respiratory and blood samples, particularly in regions with limited laboratory infrastructure.NewswiseIntelliGenome Appoints Yu Shing Bio-Tech as Exclusive Distributor for CRISPR-TB in TaiwanIntelliGenome, Inc. announced the appointment of Yu Shing Bio-Tech Co., Ltd. as its exclusive distributor in Taiwan to commercialize its CE-IVDD CRISPR-TB blood test for tuberculosis diagnostics. Under the agreement, Yu Shing Bio-Tech will handle regulatory registration with Taiwan's Food and Drug Administration, support a national multicenter clinical validation study, and drive commercialization throughout the country. The partnership aligns with IntelliGenome's strategy to expand global access to its CRISPR-based molecular diagnostics through regional distribution partnerships.NewswiseIntelligenome Announces R&D Subaward Agreement with Cornell UniversityIntelligenome announced an R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable diagnostic solution for tuberculosis as part of an NIH-funded program. The company will contribute its point-of-care testing platform to support cell-free DNA TB detection from respiratory and blood samples, aiming to enable non-sputum based diagnosis in settings with limited laboratory infrastructure. The collaboration reflects Intelligenome's focus on advancing CRISPR-based molecular diagnostics for faster and more accessible infectious disease testing.PR NewswireIntelliGenome Appoints Yu Shing Bio-Tech as Exclusive Distributor for CRISPR-TB in TaiwanIntelliGenome appointed Yu Shing Bio-Tech as its exclusive distributor for Taiwan, commercializing the CE-IVDD CRISPR-TB blood test. The partnership includes regulatory registration with the Taiwan FDA and a multicenter clinical validation study led by Dr. Jia-Yih Feng. The collaboration aims to advance tuberculosis diagnostics in Taiwan.PR NewswireIntelliGenome Receives INVIMA Approval for CRISPR-TB Blood Test and Appoints Velez Lab as Exclusive Distribution Partner in ColombiaIntelliGenome, Inc. announced that Colombia's National Institute for Food and Drug Surveillance (INVIMA) has granted sanitary registration for the CRISPR-TB Blood Test Kit under registration No. 2026RD-0009793, authorizing importation and sale of the assay in Colombia. The company has simultaneously appointed Velez Lab S.A.S. as its exclusive distribution partner for Colombia under a long-term commercial agreement to expand access to tuberculosis diagnostic solutions. IntelliGenome and Velez Lab plan to collaborate with healthcare institutions and public health stakeholders to generate clinical evidence supporting integration into tuberculosis screening and diagnostic strategies, with initial focus on pediatric and extrapulmonary tuberculosis populations.MorningstarIntelliGenome Receives INVIMA Approval for CRISPR-TB Blood Test and Appoints Velez Lab as Exclusive Distribution Partner in ColombiaIntelliGenome received INVIMA approval for its CRISPR-TB Blood Test Kit in Colombia, authorizing import and sale. The company appointed Velez Lab as exclusive distributor under a long-term agreement. The blood-based test aims to expand access to tuberculosis diagnostics in the country.PR NewswireIntelliGenome Announces Strategic Partnership with CTR Scientific to Advance CRISPR-TB in MexicoIntelliGenome, Inc. announced a strategic partnership with CTR Scientific making it the exclusive distribution partner for the CRISPR-TB Blood Test in Mexico. CTR Scientific will leverage its network to accelerate evaluation, market development, and commercialization of the test, which is CE-IVDD certified and already registered in multiple international markets. The collaboration aims to improve tuberculosis detection in Mexico, particularly for pediatric, extrapulmonary, and vulnerable populations where traditional sputum-based testing is challenging.GenomeWebIntelligenome, Cornell to Develop Low-Cost Point-of-Care Tuberculosis DiagnosticCRISPR diagnostics firm Intelligenome has entered into a research and development subaward agreement with Cornell University to develop a rapid, low-cost, portable tuberculosis diagnostic. The project, funded by the National Institutes of Health, will leverage Intelligenome's point-of-care testing platform for cell-free DNA TB detection from respiratory and blood samples. The solution integrates sample processing with CRISPR-based detection into a portable lab-in-a-tube assay designed to expand diagnostic access in areas with limited laboratory infrastructure.PR NewswireIntelligenome Announces R&D Subaward Agreement with Cornell University to Advance Rapid Point-of-Care Tuberculosis DiagnosisIntelligenome has entered into an R&D subaward agreement with Cornell University to develop a rapid, low-cost, portable tuberculosis diagnostic solution as part of an NIH-funded program. The company will contribute its CRISPR-based point-of-care testing platform to create a portable lab-in-tube assay that can detect TB from respiratory and blood samples, aiming to expand diagnostic access in settings with limited laboratory infrastructure. CEO Wilson Zhang stated the collaboration aims to advance a practical point-of-care solution for rapid TB testing in underserved regions.